tbuckley/cabot-search huggingface dataset:
THU0476 Pathogenic Relationship Between Osteoarthritis, Overweight and Inflammation
Authors: J. Polyakova, B. Zavodovsky, L. Seewordova, Y. Akhverdyan, I. Zborovskaya
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Overweight is one of the main modifiable risk factor for osteoarthritis (OA). There some data about relationship between overweight and OA progression, hypertension, dyslipidemia, impaired glucose tolerance. We suppose these diseases are linked by common pathogenetic mechanisms. Previous studies have shown that weight loss results in lower levels of adipokines and proinflammatory cytokines. We suppose that visfatin is involved in the processes of degradation of cartilage and development of inflammation in OA by stimulating of interleukin-6 and 8, tumor necrosis factor, metalloproteinase-1 and 3 production. We hypothesized that weight loss in patients with OA may reduce visfatin concentration in serum and severity of inflammation. <h3>Objectives</h3> To study dynamics of visfatin level and markers of OA severity after decreasing of body weight. <h3>Methods</h3> We observed 80 OA patients (52 females and 28 males) aged 36 to 78 years with a body mass index (BMI) of 25 to 30 kg/m<sup>2</sup>. Visfatin level in serum was determined by indirect enzyme-linked immunosorbent assay (RaiBiotech, cat No. EIA-VIS-1) with an interval of 3 months. All patients was encouraged to have hypocaloric diet with low content of animal fat and therapeutic exercise. Positive dynamics to reduce body weight by 5 kg or more for 3 months was achieved in 18 patients (23%). <h3>Results</h3> The average level of visfatin in patients with OA was 4,18±0,18 ng/ml (M±m). Patients were divided into two groups: the first group - patients who were able to reduce body weight by 5 kg or more (n=18.), The second group - patients without weight loss and with the reduction of body weight less than 5 kg (n=62). The patients of first and second groups had no significant differences in the primary estimated parameters. We noted significant improvement of pain (VAS) at rest and while walking, Lequesne and WOMAC indices, CRP level in 1-at and 2-nd groups. We revealed decreasing of of visfatin level, basal glucose level, high density lipoproteins, systolic blood pressure (SBP) in 1-st group. The patients who were able to reduce body weight by 5 kg or more had better dynamics of these indices than 2-nd group ones. <h3>Conclusions</h3> The decreasing of body weight in patients with OA of more than 5 kg improves the clinical course of OA, reduce visfatin, CRP, basal glucose levels. There may be pathogenetic links between visfatin, impaired metabolism and overweight in osteoarthritis. <h3>References</h3> Adipokines as new laboratory markers in osteoarthritis/Yury R. Akhverdyan, Boris V. Zavodovsky, Larisa E. Seewordova et al. Ann Rheum Dis 2013;72(Suppl 3):702. Significance of serum resistin determination in patients with osteoarthritis/B. Zavodovsky, D. Popov, L. Seewordova et al. Ann Rheum Dis 2011;70(Suppl 3):381. <h3>Disclosure of Interest</h3> None declared
AB0855 The Effects of PPAR Alpha Agonists (Fibrates) on Knee Pain, Function, and Stiffness in Participants from the Osteoarthritis Initiative: A Case Matched Study: Table 1.
Authors: I. Shirinsky, V. Shirinsky
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> PPAR alpha agonists, or fibrates, are used for the treatment of dyslipidemia. Fibrates are also capable to reduce pain, local and systemic inflammation, and change subchondral bone morphology. Pleiotropic properties of fibrates make them a potential drug class for the use in osteoarthritis. No study to date has evaluated fibrate effects on knee symptoms in persons with knee pain and/or knee OA. <h3>Objectives</h3> To assess the effects of fibrates on longitudinal changes in knee pain, function and stiffness measures in persons with knee pain having established OA or being at risk for OA development. <h3>Methods</h3> For the current study we used longitudinal data obtained from both Incidence and Progression Subcohorts of the Osteoarthritis Initiative (OAI), which is publically available at http://oai.epi-ucsf.org.). The outcome variables studied were Western Ontario McMaster Osteoarthritis Index (WOMAC) pain, function, and stiffness subcategories. We selected patients who had WOMAC pain score &gt;0 at baseline. The use of fibrates was defined as at least one recorded use during first three years of the study, excluding baseline use. To minimize selection bias, participants were matched into fibrate users/non-users pairs using genetic matching based on demographic characteristics, body mass index, prior knee surgery, baseline outcome measures, and Physical Activity Scale for the Elderly. The outcomes were assessed at baseline and annually until year 3. Generalized estimating equations (GEE) were used to model the relationship between outcomes and fibrate use by time interaction. <h3>Results</h3> Thirty five incident fibrate users were matched with 35 participants not receiving PPAR alpha agonists. After matching, all standardized differences of means were less than 0.05 indicating that covariates were well balanced between groups. Fibrate use by time interaction was associated with statistically significant improvement of WOMAC function and WOMAC total scores. There was also a trend towards decrease in WOMAC pain score (table). <h3>Conclusions</h3> In OA and non-OA persons with knee pain PPAR alpha agonists are associated with longitudinal improvement of knee function and trend towards decrease in knee pain. These observational findings substantiate experimental studies investigating therapeutic potential of fibrates in both early stage and advanced knee OA. <h3>Disclosure of Interest</h3> None declared
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
Authors: Andres Digenio, Richard L. Dunbar, Veronica J. Alexander, Marcus Hompesch, Linda Morrow, Richard G. Lee, Mark J. Graham, Steven G. Hughes, Rosie Yu, Walter Singleton, Brenda F. Baker, Sanjay Bhanot, Rosanne M. Crooke
Journal: Diabetes Care (2016)

OBJECTIVE To determine the effects of volanesorsen (ISIS 304801), a second-generation 2'-O-methoxyethyl chimeric antisense inhibitor of apolipoprotein (apo)C-III, on triglyceride (TG) levels and insulin resistance in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS A randomized, double-blind, placebo-controlled trial was performed in 15 adult patients with type 2 diabetes (HbA1c &amp;gt;7.5% [58 mmol/mol]) and hypertriglyceridemia (TG &amp;gt;200 and &amp;lt;500 mg/dL). Patients were randomized 2:1 to receive volanesorsen 300 mg or placebo for a total of 15 subcutaneous weekly doses. Glucose handling and insulin sensitivity were measured before and after treatment using a two-step hyperinsulinemic-euglycemic clamp procedure. RESULTS Treatment with volanesorsen significantly reduced plasma apoC-III (−88%, P = 0.02) and TG (−69%, P = 0.02) levels and raised HDL cholesterol (HDL-C) (42%, P = 0.03) compared with placebo. These changes were accompanied by a 57% improvement in whole-body insulin sensitivity (P &amp;lt; 0.001). Importantly, we found a strong relationship between enhanced insulin sensitivity and both plasma apoC-III (r = −0.61, P = 0.03) and TG (r = −0.68, P = 0.01) suppression. Improved insulin sensitivity was sufficient to significantly lower glycated albumin (−1.7%, P = 0.034) and fructosamine (−38.7 μmol/L, P = 0.045) at the end of dosing and HbA1c (−0.44% [−4.9 mmol/mol], P = 0.025) 3 months postdosing. CONCLUSIONS Volanesorsen reduced plasma apoC-III and TG while raising HDL-C levels. Importantly, glucose disposal, insulin sensitivity, and integrative markers of diabetes also improved in these patients after short-term treatment.
Phase II Trial of R-CHOP Plus Bortezomib Induction Therapy Followed By Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601
Authors: Brian G. Till, Hongli Li, Steven H. Bernstein, Richard I. Fisher, Richard Burack, Lisa M. Rimsza, Justin Floyd, Marco A. DaSilva, Dennis F. Moore, Michael LeBlanc, Jonathan W. Friedberg
Journal: Blood (2014)
Mitral Replacement: Late Results with Ball Valve Prosthesis
Authors: A STARR, M L EDWARDS
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SP0032 Calcinosis in SSC: Mystery with Different Faces and Therapeutic Approaches
Authors: S. Schinke
Journal: Annals of the Rheumatic Diseases (2015)

<h3></h3> We present the case of a 74-year-old lady with unusual rapidly progressing and extensive interstitial calcinosis. Before onset of calcinosis she was diagnosed with ANA and SCL-70 positive limited cutaneous systemic sclerosis with Raynaud9s phenomenon, sclerodactyly, telangiectasia, mild interstitial lung disease and arthritis. In the course of disease she developed a recurrent calcified synovial cyst of the spine and calcifying arthritis of hands and feet unresponsive to immunosuppression with methotrexate, leflunomide, rituximab, colchicine and abatacept. Synovia analysis revealed a predominantly cholesterol rich effusion with only low numbers of inflammatory cells. Further sites of ectopic calcifications were the spine, skin, entheses and arteries. There was no underlying renal insufficiency, hyperparathyroidism, hypercalcaemia or hyperlipidaemia. Differential diagnosis of bone metabolism, rare hereditary disorders, diagnostic work-up and treatment options of calcinosis will be discussed. <h3>Disclosure of Interest</h3> None declared
Control of the innate immune response by the mevalonate pathway
Authors: Murali K Akula, Man Shi, Zhaozhao Jiang, Celia E Foster, David Miao, Annie S Li, Xiaoman Zhang, Ruth M Gavin, Sorcha D Forde, Gail Germain, Susan Carpenter, Charles V Rosadini, Kira Gritsman, Jae Jin Chae, Randolph Hampton, Neal Silverman, Ellen M Gravallese, Jonathan C Kagan, Katherine A Fitzgerald, Daniel L Kastner, Douglas T Golenbock, Martin O Bergo, Donghai Wang
Journal: Nature Immunology (2016)
Local Anesthesia
Authors: Janet M. Torpy, Cassio Lynm, Robert M. Golub
Journal: JAMA (2011)

Local Anesthesia Administration of local anesthetic for carpal tunnel surgeryCarpal tunnel surgery L ocal anesthesia is a way to numb a specific area of the body so that a medical procedure can be done without causing pain.Some operations, many dental procedures, and different types of diagnostic tests can be done using local anesthesia alone.Local anesthesia medications do not make a person sedated or produce unconsciousness.However, sedation, in which individuals are given medications to make them comfortable and to block memory, is often given along with local anesthesia for many types of procedures.Using local anesthesia alone avoids the side effects of sedation medications and medications used to produce general anesthesia (making an individual unconscious for a procedure).Local anesthetic solutions often provide long-lasting pain relief to the area where they have been applied.Many operations, such as appendectomy (removal of the appendix), cholecystectomy (removal of the gallbladder), and open heart surgery, require general anesthesia.Other procedures, including some orthopedic surgery, urological surgery, and female reproductive surgery (including most cesarean deliveries), can be done after a person is given regional anesthesia (such as spinal anesthesia or epidural anesthesia).
THU0061 The Effect of Anti-IL-6 Receptor Antibody on Cartilage Destruction in a Mouse Model of Collagen-Induced Arthritis
Authors: M. Suzuki, Y. Bi, H. Yoshida, K. Tanaka, M. Hashizume, Y. Matsumoto
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Reports of clinical trials for RA show that the anti-IL-6 receptor antibody tocilizumab (anti-IL-6R) inhibits not only bone erosion but also joint space narrowing [1]. Cartilage destruction is thought to be partly caused by increased expression of enzymes that degrade the cartilage matrix. It has also been reported that oxidative stress is increased in patients with RA [2] and plays a key role in cartilage destruction [3]. However, it is not yet clear how anti-IL-6R inhibits cartilage destruction. <h3>Objectives</h3> The purpose of this study was to investigate the effect of anti-IL-6R on cartilage destruction and the levels of the cartilage matrix–degrading enzymes and oxidative stress in a mouse model of collagen-induced arthritis (CIA). <h3>Methods</h3> After allocating some mice to a normal group, CIA was triggered in DBA/1J mice by an intradermal injection of bovine type II collagen, and these mice were allocated to a control group or a treated group. Mice in the treated group were injected intraperitoneally with anti-mouse IL-6 receptor antibody (MR16-1). Samples of serum and hind limbs were taken at the peak of swelling (Day 36). The levels of cartilage matrix–degrading enzymes (MMP-3, MMP-13, ADAMTS4, and ADAMTS5) in serum were measured by ELISA. The level of oxidative stress – as indicated by derivatives of reactive oxygen metabolites (d-ROMs) in serum – was measured using a free radical analytical system. The length of the joint space in the hind limbs was analysed by micro-computed tomography. <h3>Results</h3> In the control group, MMP-3, MMP-13, ADAMTS5, and d-ROM were significantly higher than in the normal group. ADAMTS4 could not be detected in any mouse. The space between joints in the hind limbs was significantly narrower in the control group than in the normal group, and thicker in the MR16-1 group than in the control group (Figure 1 arrows). The arthritis score and the levels of MMP-3, MMP-13, ADAMTS5, and d-ROM were lower in the MR16-1 group than in the control group. <h3>Conclusions</h3> We demonstrated that CIA-induced joint space narrowing was accompanied by increased expression of cartilage matrix–degrading enzymes and oxidative stress. Furthermore, our results also indicated that IL-6 plays an important role in cartilage destruction. Our findings indicate that anti-IL-6R may suppress cartilage destruction by inhibiting the increased expression of cartilage matrix–degrading enzymes and oxidative stress. <h3>References</h3> Kremer et al. Arthritis Rheum. 2011; 63: 609-621. Hitchon CA et al. Arthritis Res Ther. 2004; 6: 265-278. Reed KN et al. Mol Cell Biochem. 2014; 397: 195-201. <h3>Disclosure of Interest</h3> None declared
An Evaluation of the Eisenstaedt Serological Reaction in Cancer&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Jack H. Hill, M.D.
Journal: JNCI Journal of the National Cancer Institute (1958)

The Eisenstaedt serological reaction as tested in this laboratory was found to be lacking in cancer selectivity and reproducibility.
MEDICAL EDUCATION IN THE UNITED STATES
Authors: S JARCHO
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Thomas Young (1773–1829)
Authors: George E. Ehrlich
Journal: New England Journal of Medicine (1960)

THOMAS Young — physician and linguist, physicist and Egyptologist, encyclopedist and actuary — was the perfected model of the Renaissance man. But his birth in 1773 was too late for such virtuosity to be fully appreciated, and too early for his discoveries and theories to win the support they deserved. His relative obscurity, even today, one hundred and thirty years after his death, is a paradoxical commentary on his genius.Born in Milverton, England, the first of ten children of a Quaker cloth merchant and banker, Young was entrusted to his grandfather's care for the first seven years of his . . .
Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene
Authors: Janine Schmidt, Shunyou Gong, Teresa Marafioti, Barbara Mankel, Blanca Gonzalez-Farre, Olga Balagué, Ana Mozos, José Cabeçadas, Jon van der Walt, Daniela Hoehn, Andreas Rosenwald, German Ott, Stefan Dojcinov, Caoimhe Egan, Ferran Nadeu, Joan Enric Ramis-Zaldívar, Guillem Clot, Carmen Bárcena, Vanesa Pérez-Alonso, Volker Endris, Roland Penzel, Carmen Lome-Maldonado, Irina Bonzheim, Falko Fend, Elias Campo, Elaine S. Jaffe, Itziar Salaverria, Leticia Quintanilla-Martinez
Journal: Blood (2016)
Chlamydial Infections
Authors: Julius Schachter
Journal: New England Journal of Medicine (1978)

Diagnosis of nongonococcal urethritis. One of the problems in dealing with nongonococcal urethritis is in establishing the diagnosis. Basically, it must currently be a diagnosis of exclusion, because routine diagnostic tests for the agents most likely to be involved are not readily available. Routine work-up of men with urethritis always starts with tests for gonococcal infection. Once this possibility is ruled out, an effort may be made to establish infection with H. hominis, Trichomonas vaginalis or Candida albicans, but these efforts are usually not rewarded and are probably not justified. For example, H. hominis . . .
SP0094 Chronic Care Model: A Transformation
Authors: R. Bengoa
Journal: Annals of the Rheumatic Diseases (2015)

It9s not possible to handle the chronic disease agenda without a fundamental transformation of both the delivery and financing of health care. Innovative technology (ICTs) will be fundamental element of this change but they will be difficult to embed in health care, unless the health care organizations themselves innovate. Whether or not we can reach the required scale in the transformation for a sustainable health system will depend on whether clinical and senior leadership drive service delivery out into the community and the home. There are several frameworks to drive health care in that direction. <h3>Disclosure of Interest</h3> None declared
Risk of COPD in smokers with low transfer factor
Authors: Martin R. Miller, Vito Brusasco
Journal: European Respiratory Journal (2016)

We are concerned that the paper by Harvey et al . [1] in a recent issue of the European Respiratory Journal and its accompanying editorial [2] are misleading the readership with regard to the possible association between gas transfer ( T LCO), referred to in the paper as diffusion capacity, and the subsequent risk of developing chronic obstructive pulmonary disease (COPD) in smokers. The authors selected two small groups of subjects (n=59 and 46) from within a larger dataset to compare what happened to their forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio over time. Both groups at baseline had FEV1 >80% of predicted and FEV1/FVC >0.7, but one group had T LCO >80% of predicted, and the other group had T LCO <80% of predicted and also below a lower 95% confidence limit of T LCO per cent of predicted as derived by the authors from the data of a separate set of 405 healthy nonsmokers (whose data were not disclosed). This latter extra criterion is only evident from reading the online supplement and it does not readily relate to a true population lower limit as it is based on per cent of predicted values ( vide infra ). When comparing these two groups the authors found more subjects in their "low T LCO group" had developed airflow obstruction on follow-up. The article and editorial suggest that T LCO <80% of predicted is a marker of susceptibility for developing airflow limitation and COPD in smokers. However, the authors have not assessed what happened to their subjects whose T LCO is below 80% of predicted but is also above the authors' 95% confidence limit. From figure 1 it can be seen that the true population lower 95% confidence limit in older and smaller subjects can be a long way below 80% of predicted. So it is misleading to suggest that a threshold of 80% of predicted for T LCO has any particular merit in predicting future airflow obstruction when the authors have not assessed what happened to the many subjects who will have a value below this level but above the authors' lower 95% confidence limit that defined their low T LCO group. Furthermore they claim they find a predictor of COPD and yet no evidence is offered with regard to the symptoms required for making this diagnosis. The subsequent development of COPD has not yet been proven to relate to a particular threshold value of T LCO <http://ow.ly/XAlx1>
Resident Physicians With Depression or Depressive Symptoms—In Reply
Authors: Douglas A. Mata, Marco A. Ramos, Srijan Sen
Journal: JAMA (2016)

In Reply Ms Levis and colleagues comment on our finding of high levels of depression and depressive symptoms among residents—based primarily on data from self-report inventory studies—and question whether these levels are truly elevated compared with criterion-based MDD in the general population.